Genetic variation in apolipoprotein H (β2-glycoprotein I) affects the occurrence of antiphospholipid antibodies and apolipoprotein H concentrations in systemic lupus erythematosus

Abstract

Apolipoprotein H (apoH, protein; APOH, gene) is a required cofactor for the production of antiphospholipid antibodies (APA). In this study we have examined whether genetic variation in the APOH gene affects variation in risk for systemic lupus erythematosus (SLE), occurrence of antiphospholipid antibodies (APA), anti-apoH, and plasma apoH concentrations. A total of 222 white SLE women were screened for four APOHpolymorphisms (codons 88, 247, 306, and 316) by polymerase chain reaction, and for plasma apoH concentrations by ELISA. Of these, 29.3% were positive for APA (APA-positive group) and 31.1% for anti-apoH. None of the four APOH polymorphisms were significantly associated with variation in risk for SLE. The codons 306 and 316 polymorphisms showed significant, gene-dosage effects on plasma apoH concentrations (P<0.0001) and explained 30% and 13%, respectively, of the residual variation in apoH concentrations. No significant association was observed between anti-apoH status and APOH polymorphisms or plasma apoH levels. However, plasma apoH concentrations were significantly higher in patients positive for APA than in patients negative for APA (18.5±4.0 mg/dl vs 17.1+3.8 mg/dl; P=0.02). The distribution of the Trp3l6Ser polymorphism was significantly different between the APA-positive and APA-negative groups. The frequency of the mutant allele (Ser316) was significantly lower in the APA-positive group than the APA-negative group (3.1% vs 12.1% P < 0.04), indicating that the Ser316 mutation is protective against the production of phospholipid-apoH dependent APA. Our data indicate that common genetic variation in the APOH gene is a significant determinant of plasma apoH variation in SLE patients, and the Trp3l6Ser polymorphism appears to provide protection against the production of APA in SLE patients.

Keywords

apolipoprotein H β2-glycoprotein I SLE antiphospholipid antibodies genetics

Get full access to this article

View all access options for this article.

References

1 Kotzin BL . Systemic lupus erythematosus . Cell 1996; 85: 303-306 .

2 Hahn BH . An overview of the pathogenis of systemic lupus erythematosus. In: Wallace DJ , Hahn BH (eds). Duboii Lupus Erythematosus 5th edn. Williams and Wilkins: Baltimore , 1997; pp 69-75.

3 Vyse TJ , Kotzin BL . Genetic basis of systemic lupus erythematosus . Curr Opin Immunol 1996; 8: 843-851 .

4 Arnett FC . The genetics of human lupus. In Wallace DJ , Hahn BH (eds). Dubois Lupus Erythematosus 5th edn. Williams and Wilkins: Baltimore , 1997; pp 77-117.

5 Gharavi AE , Wilson WA . Antiphospholipid antibodies. In Wallace DJ , Hahn BH (eds). Dubois Lupus Erythematosus 5th edn. Williams and Wilkins: Baltimore , 1997; pp 471-491.

6 Vaarala O . Antiphospholipid antibodies and myocardial infarction . Lupus 1998; 7 (Suppl 2): S132-S134 .

7 McNeil HP , Simpson RJ , Chesterman CN , Krilis SA . Anti-phospho-lipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: f2-glycoprotein I (apolipopro-tein H) . Proc Ntl Acad Sci USA 1990; 87: 4120-4124 .

8 Galli M , Comfurius P . Maassen C et al. Anticrdiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor . Lancet 1990; 335: 1544-1547 .

9 Jones JV , James H , Tan MH , Mansor M . Antiphospholipid antibodies require f2-glycoprotein I (apolipoprotein H) as cofactor . J Rheumatol 1992; 19: 1397-1402 .

10.

10 Arvieux J , Roussel B , Ponard D , Colomb MG . IgG2 subclass restriction of anti-fl2 glycoprotein I antibodies in autoimmune patients . Clin Exp Immunol 1994; 95: 310-315 .

11.

11 Cabiedes J , Cabral AR , Alarcön-Segovia D . Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-/32-glycoprotein-I than with antiphospholipid antibodies . J Rheumatol 1995; 22: 1899-1906 .

12.

12 Cabral AR , Cabiedes J , Alarcön-Segovia D . Antibodies to phospho-lipid-free fi2-glycoprotein-I in patients with primary antiphospholipid syndrome . J Rheumatol 1995; 22: 1894-1898 .

13.

13 Lozier J , Takahashi N , Putnam FW . Complete amino acid sequence of human plasma f2-glycoprotein I . Proc Nati Acad Sci USA 1984; 81: 3640-3644 .

14.

14 Steinkasserer A , Estaller C , Weiss E , Sim RB . Complete nucleotide and deduced amino acid sequence of human,B2-glycoprotein I . Biochem J 1991; 277: 387-391 .

15.

15 Mehdi H , Nunn M , Steel DM et al. Nucleotide sequence and expression of the human gene encoding apolipoprotein H . Gene 1991; 108: 293-298 .

16.

16 Cleve H . Genetic studies on the deficiency of,B2-glycoprotein I of human serum . Hum Genet 1968; 5: 294-304 .

17.

17 Koppe Al , Walter H . Chopra VP , Bajatzadeh M . Investigation on the genetics and population genetics of the,B2-glycoprotein I polymorph-ism . Hum Genet 1970; 9: 164-171 .

18.

18 Propert DN . The relationship of sex, smoking status, birth rank and parental age to f2-glycoprotein I levels and phenotypes in a sample of Australian Caucasian adults . Hum Genet 1978; 43: 281-288 .

19.

19 Walter H , Hilling M , Brachtel R , Hitzeroth HW . On the population genetics of f2-glycoprotein I . Hum Hered 1979; 29: 236-241 .

20.

20 Kamboh MI , Ferrell RE , Sepehrnia B . Genetic studies of human apolipoproteins. IV. Structural heterogeneity of apolipoprotein H (,B2-glycoprotein I) . Am J Hum Genet 1988; 42: 452-457 .

21.

21 Kamboh MI , Wagenknecht DR , McIntyre J . Heterogeneity of the apolipoprotein H*3 allele and its role in affecting the binding of apolipoprotein H (fl2-glycoprotein I) to anionic phospholipid . Hum Genet 1995; 95: 385-388 .

22.

22 Sanghera DK , Kristensen T , Hamman RF , Kamboh MI . Molecular basis of the apolipoprotein H (fl2-glycoprotein I) protein polymorph-ism . Hum Genet 1997; 100: 57-62 .

23.

23 Sanghera DK , Wagenknecht DR , McIntyre JA , Kamboh MI . Identification of structural mutations in the fifth domain of apolipo-protein H (,B2-glycoprotein I) which affect phospholipid binding . Hum Mol Genet 1997; 6: 311-316 .

24.

24 Steinkasserer A , Dorner C , Wurzner R , Sim RB . Human fl2-glycoprotein 1: molecular analysis of DNA and amino acid poly-morphism . Hum Genet 1993; 91: 401-402 .

25.

25 Eichner JE , Kuller LH , Kamboh MI , Ferrell RE . Phenotypic effects of apolipoprotein structure variation on lipid profiles. I. APOH and quantitative lipid measures in the Healthy Women Study . Genet Epidemiol 1989; 6: 311-318 .

26.

26 Mehdi H , Kaplan MJ , Anlar FY et al. Hepatitis B virus surface antigen binds to apolipoprotein H . J Virol 1994; 68: 2415-2424 .

27.

27 McNally T , Mackie U , Isenberg DA , Machin SJ . Immunoelectro-phoresis and ELISA techniques for assay of plasma,B2 glyco-protein-I and the influence of plasma lipids . Thromb Res 1993; 72: 275-286 .

28.

28 Mehdi H , Aston CE , Sanghera DK et al. Genetic variation in the apolipoprotein H (,B2-glycoprotein I) gene affects plasma apolipopro-tein H concentrations . Hum Genet 1999; in press (online publication No. DOI 10.1007/s004399800089).

29.

29 Galli M , Cortelazzo, Daldossi M , Barbui T . Increased levels of /2-glycoprotein I (aca-cofactor) in patients with lupus anticoagulant . Thromb Haemost 1992; 67: 386-386 .

30.

30 Oosting J , Derksen R , Entjes H et al. Lupus anticoagulant activity is frequently dependent on the presence of #2-glycoprotein I . Thromb Haemost 1992; 67: 499-502 .

31.

31 Kamboh MI , Mehdi H . Genetics of apolipoprotein H (fl2-glyco-protein I) and anionic phospholipid binding . Lupus 1998; 7(Suppl 2): S 10-S 13 .

32.

32 Koike T , Ichikawa K , Atsumi T et al. Epitopeson fi2-GPI recognized by anticardiolipin antibodies . Lupus 1998; 7(Suppl 2): S14-S17 .

33.

33 Marquis D , Victoria E , Iverson GM . fl2GPI-dependent anticardiolipin autoantibodies recognize an epitope on the first domain of fi2GPI . Lupus 1998; 7(Suppl 7): S176-S176 (abstract).

34.

34 Horbach DA , van Oort E , Tempelman MJ et al. The prevalence of a non-phospholipid-binding form of /52-glycoprotein I in human plasma. Consequences for the development of anti-fl2-glycoprotein I anti-bodies . Thromb Haemost 1998; 80: 791-797 .